PE20020323A1 - COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE) - Google Patents

COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE)

Info

Publication number
PE20020323A1
PE20020323A1 PE2001000826A PE2001000826A PE20020323A1 PE 20020323 A1 PE20020323 A1 PE 20020323A1 PE 2001000826 A PE2001000826 A PE 2001000826A PE 2001000826 A PE2001000826 A PE 2001000826A PE 20020323 A1 PE20020323 A1 PE 20020323A1
Authority
PE
Peru
Prior art keywords
inhibitors
ace
pharmaceutical composition
insulin secretion
hmg
Prior art date
Application number
PE2001000826A
Other languages
English (en)
Inventor
Marjorie Regan Gatlin
Malcolm Allison
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20020323A1 publication Critical patent/PE20020323A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: a) UN POTENCIADOR DE LA SECRESION DE INSULINA TAL COMO TOLBUTAMIDA, CLORPROPAMIDA, TOLAZAMIDA, ACETOHEXAMIDA, GLICOPIRAMIDA, GLIBENCLAMIDA, GLIMEPIRIDA, NATEGLINIDA, ENTRE OTROS Y b) INHIBIDORES DE HMG-Co-A-REDUCTASA SELECCIONADO DE ATORVASTATINA, CERIVASTATINA, FLUVASTATINA, LOVASTATINA, PITAVASTATINA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE) SELECCIONADOS DE ALACEPRIL, BENAZEPRIL, ENALAPRIL, CAPTOPRIL, DELAPRIL, RAMIPRIL, QUINAPRIL, ENTRE OTROS. LA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE HIPERGLICEMIA, HIPERINSULINEMIA, HIPERLIPIDEMIA, RESISTENCIA A LA INSULINA, RETINOPATIA
PE2001000826A 2000-08-22 2001-08-17 COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE) PE20020323A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64364200A 2000-08-22 2000-08-22

Publications (1)

Publication Number Publication Date
PE20020323A1 true PE20020323A1 (es) 2002-06-13

Family

ID=24581693

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000826A PE20020323A1 (es) 2000-08-22 2001-08-17 COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE)

Country Status (8)

Country Link
US (2) US20040087630A1 (es)
EP (1) EP1359907A2 (es)
JP (1) JP2004519424A (es)
AR (1) AR030379A1 (es)
AU (1) AU2002214952A1 (es)
PE (1) PE20020323A1 (es)
TW (1) TW200833321A (es)
WO (1) WO2002015892A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE346601T1 (de) * 2001-06-20 2006-12-15 Merck Sante Sas Verwendung von antidiabetika zur herstellung eines vernarbungsfördernden arzneimittels
US20030171407A1 (en) * 2002-03-07 2003-09-11 Upsher-Smith Laboratories, Inc. Composition for reducing blood glucose and cholesterol
CN1274668C (zh) * 2002-03-11 2006-09-13 诺瓦提斯公司 那格列奈的盐
AR039090A1 (es) * 2002-03-22 2005-02-09 Novartis Ag Combinacion de compuestos organicos
GB0217306D0 (en) * 2002-07-25 2002-09-04 Novartis Ag Compositions comprising organic compounds
US20070161700A1 (en) 2004-12-28 2007-07-12 Kowa Company, Ltd. Inhibitor for the formation of y-secretase complex
JP4955392B2 (ja) * 2004-07-01 2012-06-20 キッセイ薬品工業株式会社 血管内膜過増殖疾患の予防または治療剤
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
WO2007088705A1 (ja) * 2006-01-31 2007-08-09 Kowa Co., Ltd. 糖尿病治療剤
US8685952B2 (en) 2006-01-31 2014-04-01 Kowa Co., Ltd. Method for the treatment of diabetes
IN2014CN04119A (es) 2011-11-15 2015-07-10 Reddys Lab Ltd Dr
US11684567B2 (en) 2015-08-05 2023-06-27 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11793783B2 (en) 2015-08-05 2023-10-24 Cmpd Licensing, Llc Compositions and methods for treating an infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027974A1 (en) * 1996-12-23 1998-07-02 Merck & Co., Inc. Antidiabetic agents
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
TWI302149B (en) * 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
EP1244678A1 (en) * 1999-12-22 2002-10-02 Merck Frosst Canada Inc. Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b)
AU7705601A (en) * 2000-07-25 2002-02-05 Merck & Co Inc N-substituted indoles useful in the treatment of diabetes
EP1366012A4 (en) * 2001-02-09 2005-11-02 Merck & Co Inc 2-ARYLOXY-2-ARYLALCANO ACIDS AS USED FOR THE TREATMENT OF DIAB TES AND LIPID DISORDERS

Also Published As

Publication number Publication date
TW200833321A (en) 2008-08-16
WO2002015892A3 (en) 2003-09-04
WO2002015892A2 (en) 2002-02-28
JP2004519424A (ja) 2004-07-02
EP1359907A2 (en) 2003-11-12
US20090131404A1 (en) 2009-05-21
AU2002214952A1 (en) 2002-03-04
AR030379A1 (es) 2003-08-20
US20040087630A1 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
PE20020323A1 (es) COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE)
TR200102229T2 (tr) 3-Hidroksi-2-metilglutaril koenzim A redüktaz inhibitörlerinin diyabetik retinopati tedavisine yönelik bir ilacın imalatında kullanımı.
DE60022525D1 (de) Ramipril zur vorbeugung von kardiovaskulären vorfällen
EP1314425A4 (en) MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE
WO2005077103A3 (en) Compositions and methods for modification and prevention of sars coronavirus infectivity
EA200801164A2 (ru) Ингибиторы протеина, активирующего 5-липоксигеназу (flap)
TW200637546A (en) Combination therapy
EP1559424A3 (en) The use of inhibitors of the renin-angiotensin system
PE20040291A1 (es) COMBINACION QUE COMPRENDE UN INHIBIDOR DE HMG-CoA-REDUCTASA Y UN POTENCIADOR DE LA SECRECION DE INSULINA Y/O UN SENSIBILIZANTE DE INSULINA
CL2004000366A1 (es) USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
AR015504A1 (es) COMPOSICION FARMACEUTICA QUE COMPRENDE UNA CANTIDAD EFECTIVA DE UN INHIBIDOR DE ENZIMA CONVERSORA DE ANGIOTENSINA Y UNA CANTIDAD EFECTIVA DE UN INHIBIDORDE METALOPROTEINASA DE MATRIZ Y USO DE DICHOS COMPUESTOS PARA PREPARAR DICHA COMPOSICIoN FARMACEUTICA.
ME00578A (en) Use of gastrointestinal lipase inhibitors
WO2007106893A3 (en) Use of thrombin mutants to inhibit the anticoagulation effect of thrombin inhibitors
MX2007006279A (es) Composiciones farmaceuticas que comprenden inhibidores de nep, inhibidores del sistema de produccion de endotelina endogena, e inhibidores de hmg coa-reductasa.
MY118381A (en) Statin-carboxyalkylether combinations
HUP0002644A2 (hu) Aldóz reduktáz inhibítort és ACE inhibitort tartalmazó gyógyászati készítmények
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene
ATE340567T1 (de) Transdermales therapeutisches system zur verabreichung des partiellen dopamin-d2-agonisten aripiprazol
AR025576A1 (es) Preparacion farmaceutica para hipertension arterial
DE60112117D1 (de) Warmgeformte feste arzneizusammensetzung zur gesteuerten wirkstoffabgabe von perindopril
Souček Kombinační léčba hypertenze a dyslipidemie ke snížení kardiovaskulárního rizika.
Padwal et al. Effectiveness of ACE inhibitors in achieving blood pressure targets in hypertensive diabetics
DE60303131D1 (de) Synergistische wechselwirkung von abacavir und alovudin
PE20041062A1 (es) Preparados de combinacion de acido acetilsalicilico para la prevencion primaria de enfermedades cardiovasculares
WO2001085209A3 (en) Treating t-cell mediated diseases by modulating dr6 activity

Legal Events

Date Code Title Description
FC Refusal